United States - English - NLM (National Library of Medicine)

bausch health us llc - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 250 mg - ancobon is indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. ancobon should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to ancobon (see microbiology ). ancobon is contraindicated in patients with a known hypersensitivity to the drug. ancobon is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings).

Ireland - English - HPRA (Health Products Regulatory Authority)

viiv healthcare bv - zidovudine - concentrate for solution for infusion - 10 milligram(s)/millilitre - nucleoside and nucleotide reverse transcriptase inhibitors; zidovudine

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - vinblastine sulfate 10mg - powder for injection - 10 mg - active: vinblastine sulfate 10mg excipient: benzyl alcohol sodium chloride water for injection

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - zidovudine - syrup - 10 mg/ml - zidovudine 10 mg/ml

United States - English - NLM (National Library of Medicine)

cardinal health - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine 500 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - flucytosine - oral solution - 60mg/1ml

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

macleods pharmaceuticals limited, india - flucytosine - oral tablet - 500

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - zidovudine, quantity: 10 mg/ml - oral liquid, solution - excipient ingredients: citric acid; glycerol; maltitol solution; purified water; sodium benzoate; saccharin sodium; flavour - (1) treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex). (2) treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. new indications as at 11 may 1994: retrovir is indicated for: . treatment of adult patients with severe symptomatic human immunodeficiency virus infection (aids or advanced aids related complex); . treatment of other hiv-positive adult patients with less than 500 cd4 cells/mm3. notes: (1) the limited available data currently support the extended use of retrovir (indication 2 above). (2) the optimal dosage for these indications has not been established . combination therapy in advanced hiv infection: the addition of hivid (zalcitabine) may be considered for the management of adult patients with advanced hiv infection and cd4 + cell counts less than or equal to 200/mm3, who have received retrovir monotherapy for less than 12 months. retrovir monotherapy is still indicated as initial therapy f

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - vinblastine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; sodium chloride - used in the treatment of hodgkins' disease (stages iii and iv) in combination therapy (with adriamycin, bleomycin and dacarbazine as abvd) and in the treatment of advanced testicular carcinoma (with cisplatin and bleomycin). in the palliative treatment of lymphocytic lymphoma, histiocytic lymphoma, kaposi's sarcoma and histiocytosis x. advanced stages of mycosis fungoides. may be used in the treatment of choriocarcinoma resistant to other chemotherapeutic agents; carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

mylan ire healthcare limited - flucytosine - solution for infusion - 2.5/250 - other antimycotics for systemic use; flucytosine